Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
BMEA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 01, 2026
Report Source: 2026 1st Quarter Report
Biomea Fusion Inc. Stock Analysis BMEA
United States Health Care Micro Cap Report: Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. The company is headquartered in San Carlos, California and currently employs 41 full-time employees. The company went IPO on 2021-04-16. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The firm has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Read More Biomea Fusion Inc (BMEA) Chart
Key Statistics of Biomea Fusion Inc (BMEA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.23Volume
460.22KP/E Ratio (TTM)
-52 Week Range
Market Cap
99.05MAvg. Volume
973.71KDividend Yield
-Financial Metrics & Statements of Biomea Fusion Inc (BMEA)
FAQ's for Biomea Fusion Inc (BMEA)
- According to Musaffa’s Shariah screening methodology, Biomea Fusion Inc (BMEA) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biomea Fusion Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Biomea Fusion Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Biomea Fusion Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Biomea Fusion Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Biomea Fusion Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.